1415470-65-3Relevant academic research and scientific papers
Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes
Kong, Young Kyu,Song, Kwang-Seop,Jung, Myung Eun,Kang, Misuk,Kim, Hyeon Jung,Kim, Min Ju
supporting information, (2021/12/02)
Sodium-dependent glucose co-transporter 2 (SGLT2) has emerged as a promising drug target for the treatment of type 2 diabetes, and recently, several SGLT2 inhibitors have been approved for clinical use. A series of molecules with a C-aryl glucoside scaffo
As a new polyphenylenepolymethylenepolyisocyanate deriv. SGLT2 inhibitor
-
, (2016/10/09)
A compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney is disclosed. A pharmaceutical composition including the compound as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes is disclosed. A method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound is provided.
